rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK pathway and cancer progression.
|
22730329 |
2012 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results posit LKB1 haploinsufficiency as a risk factor for tumor progression of BRAF(V600E) mutated lung adenomas in human cancer patients.
|
23825589 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, these data indicate that PRDX1 and PRDX6 expression not only may play a key role in papillary thyroid carcinogenesis via a BRAF V600E-dependent mechanism, but their determination could be considered as potential tumor marker for indicating tumor progression in PTCs, independently of BRAF status.
|
24316730 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
|
23533235 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs.
|
20498063 |
2010 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Many melanomas harbor a mutation in this pathway, BRAF(V600E), which constitutively activates MAPK signaling and expression of downstream target genes that facilitate tumor progression.
|
25989506 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results highlight the need to evaluate the action of glucocorticoid on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown.
|
31371485 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC.
|
20230995 |
2010 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
|
26477313 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies.
|
27283860 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is assumed that BRAF(V600E) may not confer growth advantage on paediatric PTCs, and many of these cases grow slowly, suggesting that additional factors may be important for tumour progression in paediatric PTCs.
|
26584635 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.
|
25347569 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression.
|
22549727 |
2012 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results posit LKB1 haploinsufficiency as a risk factor for tumor progression of BRAF(V600E) mutated lung adenomas in human cancer patients.
|
23825589 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs.
|
20498063 |
2010 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
|
26477313 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC.
|
20230995 |
2010 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
|
23533235 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK pathway and cancer progression.
|
22730329 |
2012 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Many melanomas harbor a mutation in this pathway, BRAF(V600E), which constitutively activates MAPK signaling and expression of downstream target genes that facilitate tumor progression.
|
25989506 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is assumed that BRAF(V600E) may not confer growth advantage on paediatric PTCs, and many of these cases grow slowly, suggesting that additional factors may be important for tumour progression in paediatric PTCs.
|
26584635 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.
|
25347569 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies.
|
27283860 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression.
|
22549727 |
2012 |